Joel M. Linden

Company: Adovate
Job title: Chief Scientific Officer
Seminars:
Next Generation Adenosine Therapeutics for A2B 1:30 pm
Explain the biological importance of A2B Discuss the development route for A2B therapeutics and current challenges/opportunitiesRead more
day: Day Two